Please login to the form below

Not currently logged in
Email:
Password:

Hal Barron

This page shows the latest Hal Barron news and features for those working in and with pharma, biotech and healthcare.

GSK’s myeloma drug hits target, prompting rapid filing pledge

GSK’s myeloma drug hits target, prompting rapid filing pledge

GSK says the results show efficacy,   durability and depth of response, and Hal Barron says the drug could be ready to submit to regulators by the end of 2019. ... GSK's Hal Barron. “These data are very encouraging and I am excited by what they could

Latest news

  • Advair generics and acquisitions to hit GSK in 2019 Advair generics and acquisitions to hit GSK in 2019

    Emma Walmsley: major changes across the business in 2019. Chief executive Emma Walmsley continues to highlight the firm’s R&D rebuilding, led by new research leader Hal Barron, with 33

  • GSK gets serious about immunotherapy with Merck deal worth up to $4.2bn GSK gets serious about immunotherapy with Merck deal worth up to $4.2bn

    GSK's new R&D chief Hal Barron and CEO Emma Walmsley are determined to make up for the decision taken by former chief exec Sir Andrew Witty to sell off ... Many patients with difficult to treat tumours still don’t benefit from immunotherapies such as

  • GSK upbeat on its return to oncology market GSK upbeat on its return to oncology market

    New R&D chief Hal Barron was also on hand to underline the clinical potential of the PARP inhibitor class, including benefitting patients with other mutations. ... Hal Barron. He said the potential of PARP inhibitors has been underestimated so far, with

  • GSK buys cancer firm Tesaro for $5.1bn GSK buys cancer firm Tesaro for $5.1bn

    GSK’s head of R&D Hal Barron said that PARP inhibitors are “important medicines that have been under appreciated in terms of the impact they can have on cancer patients”,

  • Is GSK planning to exit the respiratory business? Is GSK planning to exit the respiratory business?

    Axel Hoos. He also said that GSK is considering a shake-up of R&D projects under new head of R&D Hal Barron, who joined the company from Calico, and ... Barron made much of GSK’s immunology and immuno-oncology portfolio on the company’s interim

More from news
Approximately 1 fully matching, plus 39 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Kevin Sin joins GSK Kevin Sin joins GSK

    years. Dr Hal Barron, chief scientific officer and president of research and development, GSK, said: “I am extremely excited to have Kevin join GSK. ... Sin will report to Hal Barron and will be based at the group’s San Francisco office.

  • Levinson resigns from Roche board Levinson resigns from Roche board

    He has served as CEO at Calico, Google's health research business, since its formation in September 2013 and has since been joined by former Genentech/Roche colleagues Hal Barron, David

  • Roche CMO joins Google health venture Calico Roche CMO joins Google health venture Calico

    Hal Barron among four new appointments. Dr Hal Barron has left his role as chief medical officer of Swiss pharma company Roche to join Google's recently-launched health research arm ... Dr Barron is one of four new recruits from industry and academia to

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics